Healthcare
Olema Pharmaceuticals, Inc.(OLMA)
Live Price
Offline$9.51
+0.74% today
Window Change
-27.90%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $1.25B
- Revenue Growth
- 0.0%
- EPS Growth
- +15.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Olema Pharmaceuticals, Inc. (OLMA) is a Healthcare stock with a market cap of $1.25B and listed on NASDAQ. The stock last traded around $9.51 and down 27.9% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +15.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +15.0%, free cash flow -40.4% with operating margin 0.0% and ROIC -37.0%. Stock Foundry combines OLMA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +15.0%, while operating margin sits near 0.0%.
Benchmark Edge
OLMA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OLMA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OLMA Max Drawdown
-30.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OLMA and SPY.
Company Overview
Olema Pharmaceuticals, Inc.
NASDAQ Global Select
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
- Leadership
- Sean Bohen
- IPO Date
- Nov 19, 2020
- Employees
- 96
- Street Address
- 512 2nd Street
- Mailing
- San Francisco, CA, 94107
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 243 5555
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.7
Growth
- Revenue
- 0.0%
- EPS
- +15.0%
- Free Cash Flow
- -40.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -42.9%
- ROIC
- -37.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 9.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.